|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM288077849 |
| 003 |
DE-627 |
| 005 |
20231225055447.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2018.08.012
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0960.xml
|
| 035 |
|
|
|a (DE-627)NLM288077849
|
| 035 |
|
|
|a (NLM)30170030
|
| 035 |
|
|
|a (PII)S1521-6616(18)30435-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Sthoeger, Zev
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus
|b Down-regulation by the tolerogeneic peptide hCDR1
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.10.2019
|
| 500 |
|
|
|a Date Revised 07.10.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2018 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a וֹndoleamine-2,3-dioxygenase (IDO) plays a role in immune regulation. Increased IDO activity was reported in systemic lupus erythematosus (SLE). We investigated the effects of the tolerogenic peptide hCDR1, shown to ameliorate lupus manifestations, on IDO gene expression. mRNA was prepared from splenocytes of hCDR1- treated SLE-afflicted (NZBxNZW)F1 mice, from blood samples of lupus patients, collected before and after their in vivo treatment with hCDR1 and from peripheral blood mononuclear cells (PBMC) of patients incubated with hCDR1. IDO gene expression was determined by real-time RT-PCR. hCDR1 significantly down-regulated IDO expression in SLE-affected mice and in lupus patients (treated in vivo and in vitro). No effects were observed in healthy donors or following treatment with a control peptide. Diminished IDO gene expression was associated with hCDR1 beneficial effects. Our results suggest that the hCDR1-induced FOXP3 expressing regulatory T cells in lupus are not driven by IDO but rather by other hCDR1 regulated pathways
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Cytokines
|
| 650 |
|
4 |
|a FOXP3
|
| 650 |
|
4 |
|a Immunomodulation of gene expression
|
| 650 |
|
4 |
|a Indoleamine 2,3-dioxygenase (IDO)
|
| 650 |
|
4 |
|a Systemic lupus erythematosus (SLE)
|
| 650 |
|
4 |
|a Tolerogenic peptide (hCDR1)
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a FOXP3 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Forkhead Transcription Factors
|2 NLM
|
| 650 |
|
7 |
|a Foxp3 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Indoleamine-Pyrrole 2,3,-Dioxygenase
|2 NLM
|
| 650 |
|
7 |
|a Peptide Fragments
|2 NLM
|
| 650 |
|
7 |
|a edratide
|2 NLM
|
| 650 |
|
7 |
|a 38PLP07BKC
|2 NLM
|
| 700 |
1 |
|
|a Sharabi, Amir
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zinger, Heidy
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Asher, Ilan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mozes, Edna
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 197(2018) vom: 01. Dez., Seite 34-39
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:197
|g year:2018
|g day:01
|g month:12
|g pages:34-39
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2018.08.012
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 197
|j 2018
|b 01
|c 12
|h 34-39
|